Guardant Health Inc.
Guardant Health Appoints Dr. Manuel Hidalgo Medina to Board of Directors
Summary
On July 17, 2024, Guardant Health, Inc. announced the appointment of Dr. Manuel Hidalgo Medina to its Board of Directors, effective immediately. Dr. Hidalgo, a renowned expert in oncology with extensive experience in clinical research and leadership roles, will serve on the Board until 2026. His expertise in precision oncology aligns with Guardant Health's mission to improve patient outcomes through advanced diagnostics. The appointment was also announced in a press release on July 18, 2024.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement